{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:15:50Z","timestamp":1774548950140,"version":"3.50.1"},"reference-count":207,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the mesothelial cells lining the pleural surface of the chest wall and lung. The etiology of MPM is strongly associated with prior exposure to asbestos fibers, and the median survival rate of the diagnosed patients is approximately one year. Despite the latest advancements in surgical techniques and systemic therapies, currently available treatment modalities of MPM fail to provide long-term survival. The increasing incidence of MPM highlights the need for finding effective treatments. Targeted therapies offer personalized treatments in many cancers. However, targeted therapy in MPM is not recommended by clinical guidelines mainly because of poor target definition. A better understanding of the molecular and cellular mechanisms and the predictors of poor clinical outcomes of MPM is required to identify novel targets and develop precise and effective treatments. Recent advances in the genomics and functional genomics fields have provided groundbreaking insights into the genomic and molecular profiles of MPM and enabled the functional characterization of the genetic alterations. This review provides a comprehensive overview of the relevant literature and highlights the potential of state-of-the-art genomics and functional genomics research to facilitate the development of novel diagnostics and therapeutic modalities in MPM.<\/jats:p>","DOI":"10.3390\/ijms21176342","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T08:53:43Z","timestamp":1598950423000},"page":"6342","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Genomics and Functional Genomics of Malignant Pleural Mesothelioma"],"prefix":"10.3390","volume":"21","author":[{"given":"Ece","family":"Cakiroglu","sequence":"first","affiliation":[{"name":"Izmir Biomedicine and Genome Center, Izmir 35340, Turkey"},{"name":"Department of Genome Sciences and Molecular Biotechnology, Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir 35340, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3963-2294","authenticated-orcid":false,"given":"Serif","family":"Senturk","sequence":"additional","affiliation":[{"name":"Izmir Biomedicine and Genome Center, Izmir 35340, Turkey"},{"name":"Department of Genome Sciences and Molecular Biotechnology, Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir 35340, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/CLEP.S105396","article-title":"Mesothelioma in the United States: A Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival","volume":"8","author":"Fryzek","year":"2016","journal-title":"Clin. Epidemiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102815","DOI":"10.1016\/j.critrevonc.2019.102815","article-title":"Emerging therapies in malignant pleural mesothelioma","volume":"144","author":"Cinausero","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(00)04013-7","article-title":"Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey","volume":"357","author":"Siegel","year":"2001","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1158\/0008-5472.CAN-05-4642","article-title":"Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey","volume":"66","author":"Dogan","year":"2006","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: Scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.rmed.2017.11.015","article-title":"Progress and challenges in Mesothelioma: From bench to bedside","volume":"134","author":"Blyth","year":"2018","journal-title":"Respir. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S1003","DOI":"10.21037\/jtd.2018.04.31","article-title":"Biomarkers in malignant pleural mesothelioma: Current status and future directions","volume":"10","author":"Ahmadzada","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00595-015-1275-3","article-title":"Current surgical strategies for malignant pleural mesothelioma","volume":"46","author":"Takuwa","year":"2016","journal-title":"Surg. Today"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.08.011","article-title":"The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?","volume":"107","author":"Bronte","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2008.08.014","article-title":"Functional inactivation of NF2\/merlin in human mesothelioma","volume":"64","author":"Thurneysen","year":"2009","journal-title":"Lung Cancer"},{"key":"ref_17","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: Identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"Jaurand","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000109618","article-title":"Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH","volume":"119","author":"Lindholm","year":"2007","journal-title":"Cytogenet. Genome Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5858\/arpa.2011-0215-RA","article-title":"molecular changes in mesothelioma with an impact on prognosis and treatment","volume":"136","author":"Jean","year":"2012","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_22","unstructured":"(2020, July 22). The Cancer Genome Atlas Program-National Cancer Institute, Available online: https:\/\/www.cancer.gov\/about-nci\/organization\/ccg\/research\/structural-genomics\/tcga."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/15384047.2016.1145850","article-title":"Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration","volume":"17","author":"Borczuk","year":"2016","journal-title":"Cancer Biol. Therapy"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7150\/jca.33316","article-title":"The study on copy number alteration of clear cell renal cancer in Chinese population","volume":"11","author":"Zhang","year":"2020","journal-title":"J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bbamcr.2013.06.027","article-title":"Regulation of proteolysis by human deubiquitinating enzymes","volume":"1843","author":"Eletr","year":"2014","journal-title":"Biochim. Biophys. Acta-Mol. Cell Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12013-011-9184-6","article-title":"An Emerging model for BAP1\u2019s role in regulating cell cycle progression","volume":"60","author":"Eletr","year":"2011","journal-title":"Cell. Biochem. Biophys."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature22798","article-title":"BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation","volume":"546","author":"Bononi","year":"2017","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","article-title":"Biological mechanisms and clinical significance of BAP1 mutations in human cancer","volume":"10","author":"Carbone","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1074\/mcp.RA119.001457","article-title":"Loss of BAP1 Results in growth inhibition and enhances mesenchymal\u2013epithelial transition in kidney tumor cells","volume":"18","author":"Chen","year":"2019","journal-title":"Mol. Cell. Proteom."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41419-018-1206-5","article-title":"BAP1 regulates different mechanisms of cell death","volume":"9","author":"Affar","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/cdd.2017.95","article-title":"Germline BAP1 mutations induce a Warburg effect","volume":"24","author":"Bononi","year":"2017","journal-title":"Cell Death Differ."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s41556-018-0178-0","article-title":"BAP1 links metabolic regulation of ferroptosis to tumour suppression","volume":"20","author":"Zhang","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/biology2010040","article-title":"BRCA1 and its network of interacting partners","volume":"2","author":"Christou","year":"2013","journal-title":"Biology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/gcc.22424","article-title":"Germline BAP1 alterations in familial uveal melanoma: BAP1 in familial uveal melanoma","volume":"56","author":"Rai","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Njauw, C.-N.J., Kim, I., Piris, A., Gabree, M., Taylor, M., Lane, A.M., DeAngelis, M.M., Gragoudas, E., Duncan, L.M., and Tsao, H. (2012). Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035295"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1479-5876-10-179","article-title":"BAP1 cancer syndrome: Malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs","volume":"10","author":"Carbone","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrc2068","article-title":"A mesothelioma epidemic in Cappadocia: Scientific developments and unexpected social outcomes","volume":"7","author":"Carbone","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamadermatol.2017.2330","article-title":"Genotypic and phenotypic features of BAP1 cancer syndrome: A report of 8 new families and review of cases in the literature","volume":"153","author":"Haugh","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Pastorino, S., Yoshikawa, Y., Pass, H.I., Emi, M., Nasu, M., Pagano, I., Takinishi, Y., Yamamoto, R., Minaai, M., and Hashimoto-Tamaoki, T. (2018). A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J. Clin. Oncol.","DOI":"10.1200\/JCO.2018.79.0352"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Panou, V., and Roe, O.D. (2020). Inherited genetic mutations and polymorphisms in malignant mesothelioma: A comprehensive review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124327"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrc1954","article-title":"Divorcing ARF and p53: An unsettled case","volume":"6","author":"Sherr","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.trecan.2016.11.006","article-title":"The Strange case of CDK4\/6 inhibitors: Mechanisms, resistance, and combination strategies","volume":"3","author":"Knudsen","year":"2017","journal-title":"Trends Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"495","DOI":"10.18632\/genesandcancer.138","article-title":"Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma","volume":"8","author":"Sobhani","year":"2017","journal-title":"Genes Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.neo.2017.05.003","article-title":"Combined inhibition of CDK4\/6 and PI3K\/AKT\/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells","volume":"19","author":"Bonelli","year":"2017","journal-title":"Neoplasia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejmech.2017.07.063","article-title":"Malignant pleural mesothelioma: State of the art and advanced cell therapy","volume":"142","author":"Facchetti","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_52","first-page":"1227","article-title":"Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer","volume":"55","author":"Sekido","year":"1995","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Sato, T., and Sekido, Y. (2018). NF2\/Merlin Inactivation and potential therapeutic targets in mesothelioma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19040988"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00401-019-02029-5","article-title":"An update on the CNS manifestations of neurofibromatosis type 2","volume":"139","author":"Coy","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2174\/138920310791824011","article-title":"Merlin, a \u201cmagic\u201d linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival","volume":"11","author":"Stamenkovic","year":"2010","journal-title":"Curr. Protein Pept. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Li, W., Cooper, J., Karajannis, M.A., and Giancotti, F.G. (2012). Merlin: A tumour suppressor with functions at the cell cortex and in the nucleus. EMBO Rep.","DOI":"10.1038\/sj.embor.2012.11"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","article-title":"Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK","volume":"25","author":"Poulikakos","year":"2006","journal-title":"Oncogene"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"237ra68","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts fak inhibitor sensitivity: A synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: A retrospective study","volume":"10","author":"Monica","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/0008-5472.CAN-15-0751","article-title":"Gender-specific molecular and clinical features underlie malignant pleural mesothelioma","volume":"76","author":"Archer","year":"2016","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.lungcan.2018.03.009","article-title":"Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations","volume":"119","author":"Sneddon","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1158\/1078-0432.CCR-16-1971","article-title":"Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma","volume":"23","author":"Tranchant","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1038\/onc.2012.5","article-title":"YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes","volume":"31","author":"Mizuno","year":"2012","journal-title":"Oncogene"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"113673","DOI":"10.18632\/oncotarget.22817","article-title":"Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma","volume":"8","author":"Hylebos","year":"2017","journal-title":"Oncotarget"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.emboj.7601967","article-title":"Dynamic histone H3 methylation during gene induction: HYPB\/Setd2 mediates all H3K36 trimethylation","volume":"27","author":"Edmunds","year":"2008","journal-title":"EMBO J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cell.2016.07.005","article-title":"Dual Chromatin and Cytoskeletal Remodeling by SETD2","volume":"166","author":"Park","year":"2016","journal-title":"Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/ncomms3185","article-title":"Frequency of TERT promoter mutations in human cancers","volume":"4","author":"Vinagre","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1038\/onc.2013.351","article-title":"Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma","volume":"33","author":"Tallet","year":"2014","journal-title":"Oncogene"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/1878-0261.12651","article-title":"Genetic alterations of malignant pleural mesothelioma: Association with tumor heterogeneity and overall survival","volume":"14","author":"Quetel","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1158\/1535-7163.MCT-16-0229","article-title":"Genomic landscape of malignant mesotheliomas","volume":"15","author":"Kato","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Sneddon, S., Patch, A.-M., Dick, I.M., Kazakoff, S., Pearson, J.V., Waddell, N., Allcock, R.J.N., Holt, R.A., Robinson, B.W.S., and Creaney, J. (2017). Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3382-6"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: The catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucl. Acids Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41587-019-0055-9","article-title":"The International cancer genome consortium data portal","volume":"37","author":"Zhang","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_75","unstructured":"ICGC\/TCGA (2020). Pan-cancer analysis of whole genomes consortium pan-cancer analysis of whole genomes. Nature, 578, 82\u201393."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00408-015-9814-7","article-title":"Driver gene and novel mutations in asbestos-exposed lung adenocarcinoma and malignant mesothelioma detected by exome sequencing","volume":"194","author":"Sarhadi","year":"2016","journal-title":"Lung"},{"key":"ref_77","first-page":"2331","article-title":"Genome-based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma","volume":"36","author":"Ugurluer","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","article-title":"Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing","volume":"150","author":"Imielinski","year":"2012","journal-title":"Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Uruga, H., Fujii, T., Nakamura, N., Moriguchi, S., Kishi, K., and Takaya, H. (2020). Squamous cell transformation as a mechanism of acquired resistance to tyrosine kinase inhibitor in EGFR-mutated lung adenocarcinoma: A report of two cases. Respirol. Case Rep., 8.","DOI":"10.1002\/rcr2.521"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10555-017-9726-5","article-title":"Mutations of key driver genes in colorectal cancer progression and metastasis","volume":"37","author":"Huang","year":"2018","journal-title":"Cancer Metastasis Rev."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Zimmer, K., Puccini, A., Xiu, J., Baca, Y., Spizzo, G., Lenz, H.-J., Battaglin, F., Goldberg, R.M., Grothey, A., and Shields, A.F. (2020). WRN-mutated colorectal cancer is characterized by a distinct genetic phenotype. Cancers, 12.","DOI":"10.3390\/cancers12051319"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1158\/0008-5472.CAN-16-1921","article-title":"Somatic ephrin receptor mutations are associated with metastasis in primary colorectal cancer","volume":"77","author":"Mathot","year":"2017","journal-title":"Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.7150\/jca.19582","article-title":"MAP2K1 mutation in colorectal cancer patients: Therapeutic challenge using patient-derived tumor cell lines","volume":"8","author":"Kim","year":"2017","journal-title":"J. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/annonc\/mdv022","article-title":"Genetics of breast cancer: A topic in evolution","volume":"26","author":"Shiovitz","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics Portal: An open platform for exploring multidimensional cancer genomics data: Figure 1","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_87","first-page":"pl1","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Sign."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0002-9440(10)62492-3","article-title":"Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling","volume":"166","author":"Gordon","year":"2005","journal-title":"Am. J. Pathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/bjc.2014.220","article-title":"Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma","volume":"110","author":"Zhou","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ejcdt.2014.06.005","article-title":"Role of epidermal growth factor receptor in malignant pleural mesothelioma and its value for successful chemical pleurodesis","volume":"63","author":"Hosny","year":"2014","journal-title":"Egypt. J. Chest Dis. Tuberc."},{"key":"ref_91","first-page":"181","article-title":"Activation of the PI3K-AKT pathway in human malignant mesothelioma cells","volume":"2","author":"Suzuki","year":"2009","journal-title":"Mol. Med. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.lungcan.2012.02.022","article-title":"Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)","volume":"77","author":"Montero","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s13277-012-0615-9","article-title":"PTEN protein expression in malignant pleural mesothelioma","volume":"34","author":"Agarwal","year":"2013","journal-title":"Tumour Biol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1593\/neo.101156","article-title":"Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma","volume":"13","author":"Ou","year":"2011","journal-title":"Neoplasia"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/cncr.21014","article-title":"Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells","volume":"103","author":"Vintman","year":"2005","journal-title":"Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/bjc.1990.207","article-title":"Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody","volume":"61","author":"Dazzi","year":"1990","journal-title":"Br. J. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/bjc.2013.130","article-title":"Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma","volume":"108","author":"Mezzapelle","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2174\/138945009789753200","article-title":"Molecular targets in malignant pleural mesothelioma treatment","volume":"10","author":"Pasello","year":"2009","journal-title":"Curr. Drug Targets"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Cancer and leukemia group B (CALGB 30101) gefitinib in patients with malignant mesothelioma: A phase II study by the cancer and leukemia group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1054\/bjoc.2001.1997","article-title":"Angiogenesis is an independent prognostic factor in malignant mesothelioma","volume":"85","author":"Edwards","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2005.07.010","article-title":"Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM)","volume":"51","author":"Klabatsa","year":"2006","journal-title":"Lung Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fonc.2020.00126","article-title":"Antiangiogeneic strategies in Mesothelioma","volume":"10","author":"Nowak","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/1477-3163.77274","article-title":"Role of protein kinase C \u03b2 and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism","volume":"10","author":"Salgia","year":"2011","journal-title":"J. Carcinog."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Belli, C. (2012). Role of inflammation and angiogenic growth factors in malignant mesothelioma. Malignant Mesothelioma, InTech.","DOI":"10.5772\/1648"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0092-8674(92)90169-D","article-title":"Kinesin-related proteins required for structural integrity of the mitotic spindle","volume":"70","author":"Saunders","year":"1992","journal-title":"Cell"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"R1002","DOI":"10.1016\/j.cub.2015.08.051","article-title":"The molecular biology of spindle assembly checkpoint signaling dynamics","volume":"25","author":"Musacchio","year":"2015","journal-title":"Curr. Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1101\/gad.335471.119","article-title":"The spatial regulation of condensin activity in chromosome condensation","volume":"34","author":"Lamothe","year":"2020","journal-title":"Genes Dev."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/10049","article-title":"Temporal and spatial control of cyclin B1 destruction in metaphase","volume":"1","author":"Clute","year":"1999","journal-title":"Nat. Cell Biol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Crispi, S., Calogero, R.A., Santini, M., Mellone, P., Vincenzi, B., Citro, G., Vicidomini, G., Fasano, S., Meccariello, R., and Cobellis, G. (2009). Global gene expression profiling of human pleural mesotheliomas: Identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007016"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/annonc\/mdu127","article-title":"Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications","volume":"25","author":"Suraokar","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J. Clin. Investing."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/modpathol.2011.144","article-title":"Epithelial\u2013mesenchymal transition in malignant mesothelioma","volume":"25","author":"Fassina","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/bioinformatics\/btr634","article-title":"Data-driven information retrieval in heterogeneous collections of transcriptomics data links SIM2s to malignant pleural mesothelioma","volume":"28","author":"Caldas","year":"2012","journal-title":"Bioinformatics"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/JTO.0b013e3182a59f45","article-title":"Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia","volume":"8","author":"Borrelli","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.21037\/jtd.2017.10.158","article-title":"Overexpressed genes in malignant pleural mesothelioma: Implications in clinical management","volume":"10","author":"Barone","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Turini, S., Bergandi, L., Gazzano, E., Prato, M., and Aldieri, E. (2019). Epithelial to mesenchymal transition in human mesothelial cells exposed to asbestos fibers: Role of TGF-\u03b2 as mediator of malignant mesothelioma development or metastasis via EMT event. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20010150"},{"key":"ref_120","unstructured":"Lo, S.K. (2016). Molecular Analyses of Malignant Pleural Mesothelioma. [Ph.D. Thesis, Imperial College London]."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-019-0180-0","article-title":"LOX family and ZFPM2 as novel diagnostic biomarkers for malignant pleural mesothelioma","volume":"8","author":"Kim","year":"2020","journal-title":"Biomark. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1038\/oncsis.2013.29","article-title":"Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug","volume":"2","author":"Tamminen","year":"2013","journal-title":"Oncogenesis"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lungcan.2019.11.013","article-title":"Detection of TGF-\u03b2 in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma","volume":"139","author":"Stockhammer","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Rouka, E., Vavougios, G.D., Solenov, E.I., Gourgoulianis, K.I., Hatzoglou, C., and Zarogiannis, S.G. (2017). Transcriptomic analysis of the claudin interactome in malignant pleural mesothelioma: Evaluation of the effect of disease phenotype, asbestos exposure, and CDKN2A deletion status. Front. Physiol., 8.","DOI":"10.3389\/fphys.2017.00156"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-08-2586","article-title":"Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome","volume":"69","author":"Christensen","year":"2009","journal-title":"Cancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1158\/0008-5472.CAN-10-0190","article-title":"Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma","volume":"70","author":"Christensen","year":"2010","journal-title":"Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.1158\/0008-5472.CAN-09-1595","article-title":"Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma","volume":"69","author":"Goto","year":"2009","journal-title":"Cancer Res."},{"key":"ref_128","first-page":"2536187","article-title":"SFRP tumour suppressor genes are potential plasma-based epigenetic biomarkers for malignant pleural mesothelioma","volume":"2017","author":"Cheng","year":"2017","journal-title":"Dis. Mark."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"350","DOI":"10.21037\/tlcr.2017.06.06","article-title":"Targeting the epigenome in malignant pleural mesothelioma","volume":"6","author":"McLoughlin","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: First approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Chan, J., and Tay, Y. (2018). Noncoding RNA:RNA Regulatory Networks in Cancer. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19051310"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature11233","article-title":"Landscape of transcription in human cells","volume":"489","author":"Djebali","year":"2012","journal-title":"Nature"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrm3679","article-title":"RNA in unexpected places: Long non-coding RNA functions in diverse cellular contexts","volume":"14","author":"Geisler","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tcb.2014.11.004","article-title":"The biological functions of miRNAs: Lessons from in vivo studies","volume":"25","author":"Vidigal","year":"2015","journal-title":"Trends Cell Biol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4161\/rna.20481","article-title":"The hallmarks of cancer: A long non-coding RNA point of view","volume":"9","author":"Gutschner","year":"2012","journal-title":"RNA Biol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12935-015-0185-1","article-title":"MicroRNA (miRNA) in cancer","volume":"15","author":"Reddy","year":"2015","journal-title":"Cancer Cell Int."},{"key":"ref_138","first-page":"443","article-title":"LncRNA TUC338 promotes invasion of lung cancer by activating MAPK pathway","volume":"22","author":"Zhang","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Rivera, V., Negrete-Garc\u00eda, M.C., \u00c1vila-Moreno, F., and Ortiz-Quintero, B. (2018). Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020595"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"22254","DOI":"10.18632\/oncotarget.24962","article-title":"Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy","volume":"9","author":"Mairinger","year":"2018","journal-title":"Oncotarget"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3389\/fonc.2020.00105","article-title":"Manipulating microRNAs for the treatment of malignant pleural mesothelioma: Past, present and future","volume":"10","author":"Reid","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Singh, A., Heery, R., and Gray, S. (2018). In Silico and In Vitro analyses of lncrnas as potential regulators in the transition from the epithelioid to sarcomatoid histotype of malignant pleural mesothelioma (MPM). Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19051297"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/15287394.2020.1734891","article-title":"MicroRNA-98 is a prognostic factor for asbestos-induced mesothelioma","volume":"83","author":"Kim","year":"2020","journal-title":"J. Toxicol. Environ. Health Part A"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/8628612","article-title":"MicroRNA signatures in malignant pleural mesothelioma effusions","volume":"2019","author":"Birnie","year":"2019","journal-title":"Dis. Mark."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2217\/bmm-2017-0224","article-title":"Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients","volume":"12","author":"Matboli","year":"2018","journal-title":"Biomark. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/1878-0261.12150","article-title":"A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma","volume":"12","author":"Schelch","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jtho.2017.10.016","article-title":"Dysregulated expression of the MicroRNA miR-137 and its target YBX1 contribute to the invasive characteristics of malignant pleural mesothelioma","volume":"13","author":"Johnson","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1002\/jcb.27586","article-title":"Clinical significance of serum DRAM1 mRNA, ARSA mRNA, hsa-miR-2053 and lncRNA-RP1-86D1.3 axis expression in malignant pleural mesothelioma","volume":"120","author":"Matboli","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1349-7006.2007.00676.x","article-title":"Membrane-anchored growth factors, the epidermal growth factor family: Beyond receptor ligands","volume":"99","author":"Higashiyama","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_150","first-page":"77","article-title":"Tyrosine Kinase Mutations in Human Cancer","volume":"7","author":"Lengyel","year":"2007","journal-title":"Capab. Matur. Model"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","article-title":"Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma","volume":"66","author":"Jagadeeswaran","year":"2006","journal-title":"Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","article-title":"VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours","volume":"81","author":"Ohta","year":"1999","journal-title":"Br. J. Cancer"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/onc.2010.555","article-title":"AXL regulates mesothelioma proliferation and invasiveness","volume":"30","author":"Ou","year":"2011","journal-title":"Oncogene"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/JTO.0b013e31829ceb6a","article-title":"Overexpression of EPH receptor B2 in malignant mesothelioma correlates with oncogenic behavior","volume":"8","author":"Goparaju","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/15384047.2018.1472193","article-title":"Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: A novel therapeutic approach for lung cancer and mesothelioma","volume":"19","author":"Wang","year":"2018","journal-title":"Cancer Biol. Therapy"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-8674(00)00121-5","article-title":"TGF beta signaling in growth control, cancer, and heritable disorders","volume":"103","author":"Blain","year":"2000","journal-title":"Cell"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/bjc.2012.519","article-title":"Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells","volume":"107","author":"Hoda","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.yexcr.2014.12.010","article-title":"Overexpression of activin-A and -B in malignant mesothelioma\u2013Attenuated Smad3 signaling responses and ERK activation promote cell migration and invasive growth","volume":"332","author":"Tamminen","year":"2015","journal-title":"Exp. Cell Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.bbrc.2014.04.037","article-title":"CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells","volume":"447","author":"Komiya","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/JTO.0b013e31824af2db","article-title":"Activated leukocyte cell-adhesion molecule (ALCAM) Promotes malignant phenotypes of malignant mesothelioma","volume":"7","author":"Ishiguro","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/cas.13190","article-title":"Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation","volume":"108","author":"Takeuchi","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12943-017-0633-8","article-title":"Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells","volume":"16","author":"He","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"mesothelin overexpression promotes mesothelioma cell invasion and mmp-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1111\/jcmm.13182","article-title":"Targeting YAP in malignant pleural mesothelioma","volume":"21","author":"Zhang","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1101\/gad.335562.119","article-title":"Linking cancer transcriptional addictions by CDK7 to YAP\/TAZ","volume":"34","author":"Piccolo","year":"2020","journal-title":"Genes Dev."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/jcmm.14841","article-title":"Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells","volume":"24","author":"Miao","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.18632\/oncotarget.1126","article-title":"Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: A potential therapeutic target","volume":"4","author":"Huang","year":"2013","journal-title":"Oncotarget"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nrc906","article-title":"Transcription factors as targets for cancer therapy","volume":"2","author":"Darnell","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Litwiniuk, M.M., Ro\u017cnowski, K., Filas, V., Godlewski, D.D., Stawicka, M., Kaleta, R., and Br\u0119borowicz, J. (2008). Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers. BMC Cancer, 8.","DOI":"10.1186\/1471-2407-8-100"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1172\/JCI76725","article-title":"ZEB1 drives epithelial-to-mesenchymal transition in lung cancer","volume":"126","author":"Larsen","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_171","first-page":"4143","article-title":"Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma","volume":"61","author":"Shi","year":"2001","journal-title":"Cancer Res."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-4598-12-3","article-title":"The Wilms\u2019 tumor gene (WT1) regulates E-cadherin expression and migration of prostate cancer cells","volume":"12","author":"Brett","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0463.2012.02931.x","article-title":"Expression of snail, twist, and Zeb1 in malignant mesothelioma","volume":"121","author":"Merikallio","year":"2013","journal-title":"APMIS"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.21037\/jtd.2019.03.38","article-title":"Expression of estrogen receptor beta (ER\u03b2) and its prognostic value in pleural mesothelioma","volume":"11","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1158\/1078-0432.CCR-14-3379","article-title":"Mithramycin depletes specificity protein 1 and activates p53 to mediate senescence and apoptosis of malignant pleural mesothelioma cells","volume":"22","author":"Rao","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1440-1827.2007.02080.x","article-title":"Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma","volume":"57","author":"Kushitani","year":"2007","journal-title":"Pathol. Int."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1245\/s10434-011-2142-0","article-title":"Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells","volume":"19","author":"Horio","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Pinton, G., Thomas, W., Bellini, P., Manente, A.G., Favoni, R.E., Harvey, B.J., Mutti, L., and Moro, L. (2010). Estrogen Receptor \u03b2 exerts tumor repressive functions in human malignant pleural mesothelioma via egfr inactivation and affects response to gefitinib. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0014110"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s12253-016-0181-3","article-title":"Turning back the wheel: Inducing mesenchymal to epithelial transition via wilms tumor 1 knockdown in human mesothelioma cell lines to influence proliferation, invasiveness, and chemotaxis","volume":"23","author":"Fischer","year":"2017","journal-title":"Pathol. Oncol. Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3892\/ijo.2016.3367","article-title":"Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model","volume":"48","author":"Kato","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"76577","DOI":"10.18632\/oncotarget.10428","article-title":"Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines","volume":"7","author":"Monica","year":"2016","journal-title":"Oncotarget"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygeno.2010.02.002","article-title":"Knockdown of COPA, identified by loss-of-function screen, induces apoptosis and suppresses tumor growth in mesothelioma mouse model","volume":"95","author":"Sudo","year":"2010","journal-title":"Genomics"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2009.03.016","article-title":"Malignant pleural mesothelioma: Genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets","volume":"67","author":"Roe","year":"2010","journal-title":"Lung Cancer"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2353\/ajpath.2009.080721","article-title":"Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis","volume":"174","author":"Romagnoli","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/bjc.2013.731","article-title":"An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma","volume":"110","author":"Linton","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/1535-7163.MCT-19-0724","article-title":"CRISPR screening identifies WEE1 as a combination target for standard chemotherapy in malignant pleural mesothelioma","volume":"19","author":"Xu","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1535-7163.MCT-19-0356","article-title":"Functional genomic screen in mesothelioma reveals that loss of function of BRCA1-Associated protein 1 induces chemoresistance to ribonucleotide reductase inhibition","volume":"19","author":"Okonska","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_188","unstructured":"(2020, July 22). DepMap: The Cancer Dependency Map Project at Broad Institute. Available online: https:\/\/depmap.org\/portal\/."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"ref_190","unstructured":"(2020, May 08). Broad DepMap 20Q1 Public 2020. Available online: https:\/\/depmap.org\/portal\/download."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1038\/s41467-018-06916-5","article-title":"Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration","volume":"9","author":"McFarland","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1126\/science.aac7041","article-title":"Identification and characterization of essential genes in the human genome","volume":"350","author":"Wang","year":"2015","journal-title":"Science"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucl. Acids Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: A Portal for facilitating tumor subgroup gene expression and survival analyses","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Dell\u2019Anno, I., Barbarino, M., Barone, E., Giordano, A., Luzzi, L., Bottaro, M., Migliore, L., Agostini, S., Melani, A., and Melaiu, O. (2020). EIF4G1 and RAN as Possible Drivers for Malignant Pleural Mesothelioma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21144856"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/1078-0432.CCR-17-1172","article-title":"Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition","volume":"24","author":"Badhai","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1158\/1078-0432.CCR-17-1345","article-title":"Chemical profiling of primary mesothelioma cultures defines subtypes with different expression profiles and clinical responses","volume":"24","author":"Schunselaar","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1038\/s41598-018-21200-8","article-title":"In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening","volume":"8","author":"Mazzocchi","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1158\/1078-0432.CCR-16-0844","article-title":"Patient-derived xenograft establishment from human malignant pleural mesothelioma","volume":"23","author":"Wu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"8090","DOI":"10.1158\/0008-5472.CAN-05-2312","article-title":"A Mouse model recapitulating molecular features of human mesothelioma","volume":"65","author":"Altomare","year":"2005","journal-title":"Cancer Res."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ccr.2008.01.030","article-title":"A Conditional mouse model for malignant mesothelioma","volume":"13","author":"Jongsma","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"8952","DOI":"10.1002\/jcp.26830","article-title":"Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas","volume":"233","author":"Sementino","year":"2018","journal-title":"J. Cell. Phys."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Badhai, J., Pandey, G.K., Song, J.-Y., Krijgsman, O., Bhaskaran, R., Chandrasekaran, G., Kwon, M.-C., Bombardelli, L., Monkhorst, K., and Grasso, C. (2020). Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice. J. Exp. Med., 217.","DOI":"10.1084\/jem.20191257"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1158\/0008-5472.CAN-18-4093","article-title":"Inactivation of Bap1 cooperates with losses of Nf2 and Cdkn2a to drive the development of pleural malignant mesothelioma in conditional mouse models","volume":"79","author":"Kukuyan","year":"2019","journal-title":"Cancer Res."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/0008-5472.CAN-14-1328","article-title":"Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/onc.2015.243","article-title":"Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma","volume":"35","author":"Napolitano","year":"2016","journal-title":"Oncogene"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1158\/0008-5472.CAN-15-3371","article-title":"Bap1 is a bona fide tumor suppressor: Genetic evidence from mouse models carrying heterozygous germline Bap1 mutations","volume":"76","author":"Kadariya","year":"2016","journal-title":"Cancer Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/17\/6342\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:05:32Z","timestamp":1760177132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/17\/6342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":207,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["ijms21176342"],"URL":"https:\/\/doi.org\/10.3390\/ijms21176342","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}